A. Bass

发表

Origins, practices and future of safety pharmacology.

Patricia Williams, P. Williams, A. Bass, 2004, Journal of pharmacological and toxicological methods.

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

Gary Gintant, Karluss Thomas, Alan S Bass, 2006, Journal of pharmacological and toxicological methods.

Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

G. Gintant, A. Pointon, A. Bahinski, 2020, Clinical pharmacology and therapeutics.

Current Practices in Safety Pharmacology

Dennis Murphy, Gary A. Gintant, Roger D. Porsolt, 2010 .

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug‐induced torsades de pointes

C. January, D. Roden, P. Sager, 2008, British journal of pharmacology.

Response of safety pharmacologists to challenges arising from the rapidly evolving changes in the pharmaceutical industry.

J. Valentin, A. Bass, T. Yoshinaga, 2019, Journal of pharmacological and toxicological methods.

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

J. Valentin, A. Bass, L. Kinter, 2011, Journal of pharmacological and toxicological methods.

Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance

Sherri Matis-Mitchell, S. Pettit, M. Skinner, 2015, British journal of pharmacology.

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

A. Bass, L. Kinter, P. Siegl, 2004, Journal of pharmacological and toxicological methods.

4 – MODULATION OF THE DOPAMINERGIC SYSTEM IN CARDIOVASCULAR THERAPEUTICS

A. Bass, M. Murphy, L. I. Goldberg, 1989 .

Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability.

P. Volders, J. Valentin, A. Bass, 2007, Journal of pharmacological and toxicological methods.

A. Bass, J. Foss, L. I. Goldberg, 1993, Journal of clinical pharmacology.

Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.

A. Bass, L. I. Goldberg, L. Goldberg, 1988, The American journal of cardiology.

Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.

Amy G. Aslamkhan, S. Pacchione, N. Solban, 2020, Toxicology and applied pharmacology.

The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys

A. Bass, G. Friedrichs, G. Pastino, 2008, British journal of pharmacology.

Characterizing Pharmacokinetic–Pharmacodynamic Relationships and Efficacy of PI3Kδ Inhibitors in Respiratory Models of TH2 and TH1 Inflammation

H. Houshyar, Hongshi Yu, S. Alves, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.

A. Bass, L. A. Hanson, T. A. Jackson, 2009, Journal of pharmacological and toxicological methods.

Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.

T. Fischmann, M. Altman, X. Fradera, 2019, Journal of medicinal chemistry.

Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.

J. Valentin, A. Bass, K. Olejniczak, 2005, Journal of pharmacological and toxicological methods.

Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.

A. Bass, L. I. Goldberg, J. Kohli, 1987, The Journal of pharmacology and experimental therapeutics.

Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.

M. Augustin, X. Fradera, A. Bass, 2019, Bioorganic & medicinal chemistry letters.

Is there a role for the no observed adverse effect level in safety pharmacology?

S. Authier, T. Baird, J. Valentin, 2020, Journal of pharmacological and toxicological methods.

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.

Liudmila Polonchuk, Jean-Pierre Valentin, Hugo M Vargas, 2008, Journal of pharmacological and toxicological methods.

Benchmarking safety pharmacology regulatory packages and best practice.

Alan S Bass, Mary Jeanne Kallman, Michael K Pugsley, 2008, Journal of pharmacological and toxicological methods.

Selective role of dopamine in the natriuresis produced by iso-osmotic saline infusion.

A. Bass, M. Murphy, 1991, Clinical and experimental hypertension. Part A, Theory and practice.

Moving towards better predictors of drug‐induced torsades de pointes

P. Sager, J. Valentin, A. Bass, 2008, British journal of pharmacology.

ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc).

Alan Y Chiang, Karluss Thomas, Alan S Bass, 2007, Journal of pharmacological and toxicological methods.

Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds.

John P Patterson, Carrie G Markgraf, Maria Cirino, 2005, Journal of pharmacological and toxicological methods.

Exploratory drug safety: a discovery strategy to reduce attrition in development.

Richard Morrison, John Hunter, Alan S Bass, 2009, Journal of pharmacological and toxicological methods.

Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices.

G. Tomaselli, A. Bass, L. Kinter, 2005, Journal of pharmacological and toxicological methods.

Structure Overhaul Affords a Potent Purine PI3K delta Inhibitor with Improved Tolerability.

T. Fischmann, X. Fradera, T. Guzi, 2019 .

Stereoselectivity of S- and R-sulpiride for pre- and postsynaptic dopamine receptors in the canine kidney.

A. Bass, N. W. Robie, 1984, The Journal of pharmacology and experimental therapeutics.

Effect of ring fluorination of epinephrine on its cardiovascular adrenoceptor activities.

A. Bass, A. Adejare, K. Kirk, 1990, European journal of pharmacology.

Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.

A. Bass, Gregory S Friedrichs, Leslie Patmore, 2005, Journal of pharmacological and toxicological methods.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Matthew L. Maddess, H. Houshyar, M. Altman, 2015, Journal of medicinal chemistry.

Contrasting effects of dopexamine hydrochloride on electrolyte excretion in canine kidney.

A. Bass, 1990, The Journal of pharmacology and experimental therapeutics.

Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug.

A. Bass, M. Murphy, J. Kohli, 1989, Journal of cardiovascular pharmacology.

A Historical View and Vision into the Future of the Field of Safety Pharmacology.

Jean-Pierre Valentin, Alan S Bass, J. Valentin, 2015, Handbook of experimental pharmacology.

Presynaptic effects of dopexamine hydrochloride in the canine kidney

A. Bass, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Introduction to nonclinical safety pharmacology and the safety pharmacology society.

A. Bass, L. Kinter, H. Vargas, 2004, Journal of pharmacological and toxicological methods.

Role of endogenous dopamine in the natriuresis accompanying various sodium challenges.

A. Bass, M. Murphy, 1990, American journal of hypertension.

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies.

M Markert, J. Valentin, A. Bass, 2009, Journal of pharmacological and toxicological methods.

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).

J. Lachowicz, C. Farley, Zhiwei Yang, 2013, Bioorganic & medicinal chemistry letters.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Andrew M Haidle, Matthew L. Maddess, H. Houshyar, 2015, Journal of medicinal chemistry.